Oppenheimer analyst Suraj Kalia initiates coverage on Intersect ENT (NASDAQ: XENT) with a Perform rating.The analyst comments "Intersect's line of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE